Amendments to the Claims:

The following is a complete list of claims indicating the changes incorporated by the present amendment and replacing all prior versions of the claims. Any claims canceled herein and all deletions made in claims that are not canceled herein are done so without prejudice to being re-instituted at a later date in this or a related application.

Listing of Claims:

Claims 1-28 (canceled)

Claim 29 (currently amended): A layered oral dosage tablet comprising an immediate-release layer and a sustained-release layer, and comprising the following as active ingredients distributed between said immediate-release layer and said sustained-release layer, the listed weight percents representing the proportion of each ingredient in the immediate-release layer with the balance of each ingredient in the sustained-release layer ~~in the following approximate proportions expressed as relative weight percents~~:

	Dosage in Milligrams	Immediate-Release Layer	~~Sustained-Release Layer~~
Magnesium L-ascorbate	80-3300	40-60%	~~balance~~
2-Amino-2-deoxy-D-glucose	75-2500	40-60%	~~balance~~
L-lysine monohydrochloride	150-5000	40-60%	~~balance~~
N-acetyl-L-cysteine	80-4000	40-60%	~~balance~~
Quercetin	6.0-3000	40-60%	~~balance~~
L-Selenomethionine	0.05-1.0	100%	
Copper sulfate	0.4-14	100%	
Zinc picolinate	7.0-380	40-60%	~~balance~~

Claims 30-48 (canceled)

Claim 49 (withdrawn): A unit dosage form for the treatment of herpes simplex and conditions giving rise thereto, said unit dosage form being a vaginal dosage form selected from the group consisting of vaginally appropriate suppositories, creams, tablets and gels, comprising as active ingredients:

(a) about 1.3 μg/mL to about 30 μg/mL of ascorbic acid,

(b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-glucose,

(c) about 0.06 μg/mL to about 8.5 μg/mL of zinc sulfate, and

(d) about 1.6 μg/mL to about 23 μg/mL of L-lysine hydrochloride.

Claim 50 (withdrawn): A unit dosage form in accordance with claim **49** further comprising as an active ingredient copper sulfate in a concentration ranging from about 0.4 μg/mL to about 15 μg/mL.

Claim 51 (withdrawn): A unit dosage form in accordance with claim **49** further comprising as an active ingredient quercetin in a concentration ranging from about 0.12 μg/mL to about 2.75 μg/mL.

Claim 52 (withdrawn): A unit dosage form in accordance with claim **49** further comprising as an active ingredient heparin sodium in a concentration ranging from about 0.6 unit/mL to about 8 units/mL.

Claim 53 (withdrawn): A unit dosage form in accordance with claim **49** further comprising as an active ingredient quercetin in a concentration ranging from about 0.12 μg/mL to about 2.75 μg/mL and heparin sodium in a concentration ranging from about 0.6 unit/mL to about 8 units/mL.

Claim 54 (withdrawn): A unit dosage form in accordance with claim **49** further comprising as an active ingredient quercetin in a concentration ranging from about 0.12 μg/mL to about 2.75 μg/mL, heparin sodium in a concentration ranging from about 0.6 unit/mL to about 8 units/mL, and N-acetylcysteine in a concentration ranging from about 0.6 units/mL to about 8 units/mL.

Claim 55 (withdrawn): A unit dosage form for the treatment of herpes simplex and conditions giving rise thereto, said unit dosage form being a mucosal dosage form selected from the group consisting of vaginally appropriate suppositories, creams, tablets and gels, comprising as active ingredients:

(a) ascorbic acid,

(b) 2-amino-2-deoxy-D-glucose,

(c) zinc sulfate, and

(d) L-lysine hydrochloride.

Claim 56 (withdrawn): A unit dosage form in accordance with claim **55** in which the concentrations of said active ingredients are as follows:

(a) about 1.3 μg/mL to about 30 μg/mL of ascorbic acid,

(b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-glucose,

(c) about 0.06 μg/mL to about 8.5 μg/mL of zinc sulfate, and

(d) about 1.6 μg/mL to about 23 μg/mL of L-lysine hydrochloride.

Claim 57 (withdrawn): A unit dosage form in accordance with claim **55** further comprising as an active ingredient copper sulfate in a concentration ranging from about 0.4 μg/mL to about 15 μg/mL.

Claim 58 (withdrawn): A unit dosage form in accordance with claim **55** further comprising as an active ingredient heparin sodium in a concentration ranging from about 0.6 units/mL to about 8 units/mL.

Claim 59 (withdrawn): A unit dosage form in accordance with claim **55** further comprising as active ingredients copper sulfate in a concentration ranging from about 0.4 μg/mL to about 15 μg/mL and heparin sodium in a concentration ranging from about 0.6 units/mL to about 8 units/mL.

Claim 60 (withdrawn): A unit dosage form in accordance with claim **55** further comprising as an active ingredient N-acetyl-L-cysteine in a concentration ranging from about 0.02 mg/mL to about 0.5 mg/mL.

Claim 61 (withdrawn): A unit dosage form in accordance with claim **55** further comprising as an active ingredient L-2-oxothiazolidine-4-carboxylate in a concentration ranging from about 0.02 mg/mL to about 0.5 mg/mL.

Claim 62 (withdrawn): A unit dosage form for the treatment of herpes simplex and conditions giving rise thereto, said unit dosage form being a topical dermal dosage form selected from the group consisting of topical lotions, gels, creams, and emulsions, comprising as active ingredients:

(a) ascorbic acid,
(b) 2-amino-2-deoxy-D-glucose,
(c) zinc sulfate, and
(d) L-lysine hydrochloride.

Claim 63 (withdrawn): A unit dosage form in accordance with claim **62** in which the concentrations of said active ingredients are as follows:

(a) about 1.3 μg/mL to about 30 μg/mL of ascorbic acid,
(b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-glucose,
(c) about 0.06 μg/mL to about 8.5 μg/mL of zinc sulfate, and
(d) about 1.6 μg/mL to about 23 μg/mL of L-lysine hydrochloride.

Claim 64 (withdrawn): A unit dosage form in accordance with claim **63** further comprising as an active ingredient Cu^{+2} in a concentration ranging from about 0.15 μg/mL to about 15 μg/mL.

Claim 65 (withdrawn): A unit dosage form in accordance with claim **64** further comprising as an active ingredient quercetin in a concentration ranging from about 0.12 μg/mL to about 2.75 μg/mL.

Claim 66 (withdrawn): A unit dosage form in accordance with claim **65** further comprising as an active ingredient heparin sodium in a concentration ranging from about 0.6 unit/mL to about 8 units/mL.

Claim 67 (withdrawn): A unit dosage form in accordance with claim **66** further comprising as an active ingredient D,α-tocopherol in a concentration ranging from about 16 μg/mL to about 1600 μg/mL.

Claim 68 (withdrawn): A unit dosage form in accordance with claim **67** in which said D,α-tocopherol is in the form of D,α-tocopherol nicotinate in a concentration ranging from about 19 μg/mL to about 2600 μg/mL.

Claim 69 (withdrawn): A unit dosage form in accordance with claim **67** in which said D,α-tocopherol is in the form of D,α-tocopherol succinate in a concentration ranging from about 19 μg/mL to about 2500 μg/mL.